Evaluate

September 13, 2018

Another must-have oncolytic virus asset for big pharma

Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two…

February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

July 03, 2017

Therapy focus – Opdivo and Livatag could add to liver cancer options

December 13, 2016

Setbacks fail to stifle oncolytic virus business development

June 29, 2016

Bayer quietly claims its liver cancer prize

February 19, 2016

Hopes rise for a liver cancer breakthrough in 2016

April 30, 2015

Adcom puts T-Vec on track to underwhelm